Bill Baruch, Founder, Blue Line Capital

He bought it this week. CAT covers industrials from mining to energy and rails.They delivered one of the best quarterly earnings, then broke to new highs. This plays into the rotation theme in which he favours industrials, healthcare and energy in the second half of this year, though not tech.

They hit all-time highs, then dropped 20% after reporting last week. He still likes this infrastucture company though. CAT is better industrial play, however.

There's been underinvestment in oil while the world demands more oil. Chevron had a solid quarter despite lower oil prices last quarter, but he expects higher prices ahead. One of his top holdings.

He took some money out of tech and put it into healthcare, which has seen an increase lately. He just added Amgen who delieverd a terrific report. He will continue to rally in the second half this year, will outperform tech.

They've done a great job extending resource life. He's bullish oil.

It's been a bull market this year, but he fears a pullback in August-October. It's won't derail the overall rally; we can finish the year at record highs. Given yesterday's GDP data, we're not talking soft landing anymore, but maybe no landing. The Fed could hike once or twice more and that could throw off the market. He has been trimming big tech like Apple, Microsoft and Amazon because of overweighting in his portfolio. He hit a home run with tech this year, so he wants to be ready (to buy dips) in the second half of this year. He's seeking outperformance in healthcare, niche industrials and small caps. He remains bullish tech. He hols 8-9% cash. He can go shopping if there's a pullback.

He added more recently. Permian production hit a record. Saudi Arabia wants to cut more oil and raise prices. Also, he's bullish China, because there's little downside going forward.

Was upgraded today. This is in his top 10. In 13 years, Uber has hit 11,000 cities. Now, they're turning a profit and free cash flow is accelerating. Likes their diversification of revenue, like trucking. But you can't enter it at this level as it's above technical support. Loves the stock.

He bought it last week to diversify and get more exposure in pharmaceuticals. They report next week. Compare to Abbvie which just surprised with drug sales. There's some FT overhang, but shares have been bottoming out recently. If they announce good results, investors will chase this next week.

Loves how they shifted their franchise model. Operating margins have jumped and net sales rose 11% YTD. It's consolidating sideways, but expects a breakout. But if it falls below $270 there could be a short-term rollover.

It reports next week. The Permian is increasing production this year.

Banks reported their Q2 today. JPM's loan-loss provisions are $100 billion lower a year ago if you strip out First Republic. That says something about the trajectory of the economy. Add to that the CEO's bullish comments about the economy and his bank's forecast. Without First Rep., they beat profits at 40%, a 67% profit rise with FR. Massive.

A core holding. It performed well, though down 8% this year. Revenue is up 13%, though costs up 16%. Their medical ratio is at 83% vs. 81% last year, but in line with the street. Shares are jumping today on earnings.

Is excited about Wednesday's earnings report, looking for a big rise in revenues. Shares have been on a tear. Treat this like a commodity stock--volatile. China will be positive and there's already momentum in this stock. He expects shares to top $300.

He remains bullish in AI. No one can catch Nvidia, but AMD would be #2. AI will continues to expand as various companies like Schlumberger adopt AI technology. But beware if AMD breaks below $100-105.